Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | MAPT | P10636 | 1/20 | 0.89 |
| ▸ | PPARG | P37231 | 7/20 | 0.76 |
| ▸ | FABP2 | P12104 | 2/20 | 0.76 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.76 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.65 |
| ▸ | PPARD | Q03181 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofibric Acid SCHEMBL2227936 | 0.94 | PPARA (1.00) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL102826 | 0.94 | PPARA (1.00) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL28722594 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL11798397 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL11798234 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL10634899 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL317991 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL28571877 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| Clofibric Acid SCHEMBL11798560 | 0.91 | PPARA (0.93) | PPARACYP1A2CYP3A4MEN1KMT2A | |
| SCHEMBL9320807 | 0.89 | PPARA (0.89) | PPARACYP1A2CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4119633-A | HYPOLIPEMIC, HYPOCHOLESTRIC AGENTS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1978-10-10 | — | — | US | disclosed |
| US-3979405-A | HYPOLIPEMIC AND HYPOCHOLESTERIC AGENTS | GYOGYSZER- ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | PPARA 1060/4885CYP1A2 214/4885CYP3A4 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.